INTRODUCTION: The major substrate underlying amphetamine (AMPH)-induced locomotor activity is associated with dopamine forebrain circuits. Brain regions associated with AMPH-induced locomotor activity express high levels of retinoid receptors. However, the role of these transcription factors in dopamine-mediated effects remains poorly understood. Two nuclear receptor families, the retinoic acid receptors (RAR) and the retinoid X receptors (RXR), transduce retinoic acid signal. RARs are specifically involved in retinoid signaling, whereas RXRs also participate in other signaling pathways as partners for other nuclear receptors such as Nur77, an orphan member of the nuclear receptor family expresses in dopamine system. MATERIALS AND METHODS: To explore the role of retinoid receptors and Nur77 in AMPH-induced locomotor activity, we administered selective retinoid receptor drugs in combination with AMPH in adult wild-type and Nur77-deficient mice. At a low dose, AMPH similarly increased ambulatory activity in wild-type and Nur77-deficient mice, while it did not alter non-ambulatory activity. RESULTS AND DISCUSSION: At a high dose, AMPH did not alter ambulatory activity anymore, while non-ambulatory activity strongly increased in wild-type mice. Nur77-deficient mice still displayed a higher ambulatory activity with no change in non-ambulatory activity. HX531, a synthetic RXR antagonist, blocks AMPH-induced ambulatory activity, whereas RAR drugs tested remained without effect. Interestingly, the effect of HX531 was abolished in Nur77-deficient mice, suggesting that this orphan nuclear receptor is essential for the action of the RXR drug. CONCLUSION: This study shows that RXR and Nur77 participate in AMPH-induced locomotor activity and prompts for further investigations on the role of Nur77 and RXR in addiction and reward-related behaviors.
INTRODUCTION: The major substrate underlying amphetamine (AMPH)-induced locomotor activity is associated with dopamine forebrain circuits. Brain regions associated with AMPH-induced locomotor activity express high levels of retinoid receptors. However, the role of these transcription factors in dopamine-mediated effects remains poorly understood. Two nuclear receptor families, the retinoic acid receptors (RAR) and the retinoid X receptors (RXR), transduce retinoic acid signal. RARs are specifically involved in retinoid signaling, whereas RXRs also participate in other signaling pathways as partners for other nuclear receptors such as Nur77, an orphan member of the nuclear receptor family expresses in dopamine system. MATERIALS AND METHODS: To explore the role of retinoid receptors and Nur77 in AMPH-induced locomotor activity, we administered selective retinoid receptor drugs in combination with AMPH in adult wild-type and Nur77-deficient mice. At a low dose, AMPH similarly increased ambulatory activity in wild-type and Nur77-deficient mice, while it did not alter non-ambulatory activity. RESULTS AND DISCUSSION: At a high dose, AMPH did not alter ambulatory activity anymore, while non-ambulatory activity strongly increased in wild-type mice. Nur77-deficient mice still displayed a higher ambulatory activity with no change in non-ambulatory activity. HX531, a synthetic RXR antagonist, blocks AMPH-induced ambulatory activity, whereas RAR drugs tested remained without effect. Interestingly, the effect of HX531 was abolished in Nur77-deficient mice, suggesting that this orphan nuclear receptor is essential for the action of the RXR drug. CONCLUSION: This study shows that RXR and Nur77 participate in AMPH-induced locomotor activity and prompts for further investigations on the role of Nur77 and RXR in addiction and reward-related behaviors.
Authors: François Gilbert; Marc Morissette; Michel St-Hilaire; Brigitte Paquet; Claude Rouillard; Thérèse Di Paolo; Daniel Lévesque Journal: Biol Psychiatry Date: 2006-08-07 Impact factor: 13.382
Authors: T Yamauchi; H Waki; J Kamon; K Murakami; K Motojima; K Komeda; H Miki; N Kubota; Y Terauchi; A Tsuchida; N Tsuboyama-Kasaoka; N Yamauchi; T Ide; W Hori; S Kato; M Fukayama; Y Akanuma; O Ezaki; A Itai; R Nagai; S Kimura; K Tobe; H Kagechika; K Shudo; T Kadowaki Journal: J Clin Invest Date: 2001-10 Impact factor: 14.808
Authors: Isabelle Ethier; Geneviève Beaudry; Michel St-Hilaire; Jeff Milbrandt; Claude Rouillard; Daniel Lévesque Journal: Neuropsychopharmacology Date: 2004-02 Impact factor: 7.853
Authors: Matthew James Girgenti; Laura K Nisenbaum; Franklin Bymaster; Rosemarie Terwilliger; Ronald S Duman; Samuel Sathyanesan Newton Journal: J Neurochem Date: 2010-01-13 Impact factor: 5.372
Authors: A Higuera-Matas; G L Montoya; S M Coria; M Miguéns; C García-Lecumberri; E Ambrosio Journal: Curr Neuropharmacol Date: 2011-03 Impact factor: 7.363
Authors: Marco D Carpenter; Qiwen Hu; Allison M Bond; Sonia I Lombroso; Kyle S Czarnecki; Carissa J Lim; Hongjun Song; Mathieu E Wimmer; R Christopher Pierce; Elizabeth A Heller Journal: Nat Commun Date: 2020-01-24 Impact factor: 14.919
Authors: Chirag Upreti; Caitlin M Woodruff; Xiao-Lei Zhang; Michael J Yim; Zhen-Yu Zhou; Andrew M Pagano; Dina S Rehanian; Deqi Yin; Eric R Kandel; Patric K Stanton; Russell E Nicholls Journal: Sci Rep Date: 2021-03-10 Impact factor: 4.379